Fierce Pharma October 18, 2023
UCB is on an approval roll. Within hours of each other, the Brussels-based company has scored FDA green lights for plaque psoriasis treatment Bimzelx and for generalized myasthenia gravis (gMG) drug Zilbrysq.
Not only that, the Zilbrysq endorsement is UCB’s second in the indication this year, coming on top of the FDA signing off on Rystiggo in June.
The thumbs-up for Zilbrysq is for adults with gMG who are anti-acetylcholine receptor (AChR) antibody-positive. The medicine becomes the first once-daily, subcutaneous gMG-targeted therapy that can be self-administered, according to UCB.
The company acquired the drug in a $2.5 billion buyout of Ra Pharmaceuticals in 2019, paying more than a 100% premium to gain what it believed was a potential blockbuster.
...Today's Sponsors
Today's Sponsor